Photo taken from
Gonzalo Carreño Gómez-Tarragona/X
Jun 17, 2024, 01:15
Jean-Jacques Kiladjian: The new findings of Proud-Continuation PV randomized trial
Jean-Jacques Kiladjian, Professor of Clinical Pharmacology at Paris Diderot University, shared a post on X:
“Don’t miss the new findings of Proud-Continuation PV randomized trial showing the correlation between JAK2 mutation reduction with ropeginterferon alpha 2b and better event-free survival!
Molecular response is a meaningful goal of therapy in PV.”
Source: Jean-Jacques Kiladjian/X
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Feb 21, 2025, 13:29
Feb 21, 2025, 13:07
Feb 21, 2025, 13:06
Feb 21, 2025, 13:03
Feb 21, 2025, 13:00
Feb 21, 2025, 12:53
Feb 21, 2025, 12:41
Feb 21, 2025, 12:39